TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
4.120
-0.090 (-2.14%)
Nov 20, 2024, 4:00 PM EST - Market closed
TScan Therapeutics Employees
TScan Therapeutics had 154 employees as of December 31, 2023. The number of employees increased by 16 or 11.59% compared to the previous year.
Employees
154
Change (1Y)
16
Growth (1Y)
11.59%
Revenue / Employee
$60,792
Profits / Employee
-$722,747
Market Cap
219.89M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 154 | 16 | 11.59% |
Dec 31, 2022 | 138 | 33 | 31.43% |
Dec 31, 2021 | 105 | 47 | 81.03% |
Dec 31, 2020 | 58 | - | - |
Related Stocks
Company Name | Employees |
---|---|
High Tide | 1,550 |
Inogen | 834 |
Sutro Biopharma | 302 |
biote | 194 |
Utah Medical Products | 190 |
Genfit | 159 |
Zentalis Pharmaceuticals | 124 |
aTyr Pharma | 59 |
TCRX News
- 15 days ago - TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire
- 6 weeks ago - TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - GlobeNewsWire
- 3 months ago - TScan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology - Seeking Alpha
- 3 months ago - TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - TScan Therapeutics Announces Updates to its Board of Directors - GlobeNewsWire
- 6 months ago - TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 months ago - TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies - GlobeNewsWire